Pulse Biosciences, Inc. (NASDAQ: PLSE) reported Q2 EPS of ($0.54).

“Our progress in developing clinical applications for Nano-Pulse Stimulation continues to accelerate through 2018 as we move additional projects into the clinic and further build the portfolio of scientific evidence of our mechanism of action,” stated Darrin Uecker, President and Chief Executive Officer. “We are mid-way through 2018 and are excited not only as to the progress made so far but the opportunity for additional advancements during the remainder of 2018.”

For earnings history and earnings-related data on Pulse Biosciences, Inc. (PLSE) click here.